Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures

Journal of Perinatology

Volumn 33, Issue 11, 2013, Pages 841-846

  Maitre, N L ^a,b   Smolinsky, C ^a,b   Slaughter, J C ^a   Stark, A R ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

Antiepileptic; Cerebral palsy; Neonate

Indexed keywords

ETIRACETAM; PHENOBARBITAL;

ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; CEREBRAL PALSY; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; ELECTROGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; INFANTILE SPASM; INTERPERSONAL COMMUNICATION; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SIDE EFFECT;

ANTICONVULSANTS; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PHENOBARBITAL; PIRACETAM; RETROSPECTIVE STUDIES; SEIZURES;

EID: 84887119738     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2013.116     Document Type: Article

References (46)

1. Moster D, Wilcox AJ, Vollset SE, Markestad T, Lie RT. Cerebral palsy among term and postterm births. JAMA 2010; 304(9): 976-982.
2. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371(9608): 261-269.
3. Yeargin-Allsopp M, Van Naarden Braun K, Doernberg NS, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008; 121(3): 547-554.
4. Perez A, Ritter S, Brotschi B, Werner H, Caflisch J, Martin E et al. Long-term neurodevelopmental outcome with hypoxic-ischemic encephalopathy. Journal of Pediatrics 2013; 163(2): 454-459.
5. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 2012; 126: 1143-1172.
6. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292(19): 2357-2365.
7. Long A, Moran P, Robson S. Outcome of fetal cerebral posterior fossa anomalies. Prenat Diagn 2006; 26(8): 707-710.
8. Gillam-Krakauer M, Carter BS. Neonatal hypoxia and seizures. Pediatr Rev 2012; 33(9): 387-397.
9. Sivaswamy L. Approach to neonatal seizures. Clin Pediatr (Phila) 2012; 51(5): 415-425.
10. van Rooij LGM, Hellstrom-Westas L, de Vries LS. Treatment of neonatal seizures. Semin Fetal Neonatal Med 2013; 18(4): 1-7.
11. Cilio MR, Ferriero DM. Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med [Internet]. 2010; 15(5): 293-298.
12. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999; 341(7): 485-489.
13. Castro Conde JR, Hernandez Borges AA, Domenech Mart?nez E, Gonzalez Campo C, Perera Soler R. Midazolam in neonatal seizures with no response to phenobarbital. Neurology 2005; 64(5): 876-879.
14. Lo scher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia 2012; 53(Suppl 8): 12-25.
15. Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 2002; 99(23): 15089-15094.
16. Sulzbacher S, Farwell JR, Temkin N, Lu AS, Hirtz DG. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr (Phila) 1999; 38(7): 387-394.
17. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322(6): 364-369.
18. Park S-P, Kwon S-H. Cognitive Effects of Antiepileptic Drugs. J Clin Neurol 2008; 4(3): 99.
19. Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy RR. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011; 26(4): 465-470.
20. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: Safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011; 15(1): 1-7.
21. Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008; 39(2): 77-79.
22. Lee C-Y, Chen C-C, Liou H-H. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 2009; 158(7): 1753-1762.
23. Yan H-D, Ishihara K, Seki T, Hanaya R, Kurisu K, Arita K et al. Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca2 channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER). Brain Res Bull 2013; 90: 142-148.
24. Yang X-F, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007; 48(10): 1861-1869.
25. Meehan AL, Yang X, Yuan L-L, Rothman SM. Levetiracetam has an activitydependent effect on inhibitory transmission. Epilepsia 2012; 53(3): 469-476.
26. Brunquell PJ, Glennon CM, DiMario FJ, Lerer T, Eisenfeld L. Prediction of outcome based on clinical seizure type in newborn infants. Pediatr 2002; 140(6): 707-712.
27. Voress JMT. Developmental Assessment of Young Children. PRO-ED: Austin, TX, 1998.
28. Albers C GA. Test review: Bayley Scales of Infant and Toddler Development, Third Edition. J Psychoeduc Assess 2007; 25(2): 180-190.
29. Kuban K, Allred E, OShea M, Paneth N, Pagano M, Leviton A. An algorithm for identifying and classifying cerebral palsy in young children. J Pediatr 2008153 4: 466-472.
30. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8-14.
31. Palisano RJ, Rosenbaum P, Bartlett D, Livingston MH. Content validity of the expanded and revised Gross Motor Function Classification System. Dev Med Child Neurol 2008; 50(10): 744-750.
32. Kim J-S, Kondratyev A, Tomita Y, Gale K. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia 2007; 48(s5): 19-26.
33. Forcelli PA, Janssen MJ, Vicini S, Gale K. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann Neurol 2012; 72(3): 363-372.
34. Shankaran S. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol 2002; 187(1): 171-177.
35. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA et al. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. N Engl J Med 2000; 337(7): 466-471.
36. Ries M. Cognitive effects of older anticonvulsants in children with epilepsy: a review and critique of the literature. J Pediatr Pharmacol Ther 2003; 8(2): 115-131.
37. Kilicdag H, Dagl?oglu K, Erdogan S, Guzel A, Sencar L, Polat S et al. The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev 2013; 89(5): 355-360.
38. Stienen MN, Haghikia A, Dambach H, Thone J, Wiemann M, Gold R et al. Antiinflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFb1 regulation. Br J Pharmacol 2010; 162(2): 491-507.
39. Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth RD et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res 2012; 73(1): 24-30.
40. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76(4): 383-389.
41. Tulloch JK, Carr RR, Ensom MHH. A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther 2012; 17(1): 31-44.
42. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011; 159(1): 152-153.
43. Cormier J, Chu CJ. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. Neuropsychiatr Dis Treat 2013; 9: 295.
44. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011; 44(4): 265-269.
45. Oztekin O, Kalay S, Tezel G, Akcakus M, Oygur N. Can we safely administer the recommended dose of phenobarbital in very low birth weight infants? Childs Nerv Syst 2013; 29(8): 1353-1357.
46. Touw DJ, Graafland O, Cranendonk A, Vermeulen RJ, Van Weissenbruch MM. Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 2000; 12(2): 111-116.